Cryoglobulinemia Vasculitis

American Journal of Medicine

Volumn 128, Issue 9, 2015, Pages 950-955

  Cacoub, Patrice ^a,b,c,d   Comarmond, Cloe ^a,b,c,d   Domont, Fanny ^a,d   Savey, Léa ^a,d   Saadoun, David ^a,b,c,d  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c CNRS   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cryoglobulinemia vasculitis; Cryoglobulins; HCV; Prognosis; Treatment

Indexed keywords

COMPLEMENT COMPONENT C4; CORTICOSTEROID; CRYOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PARAPROTEIN; RHEUMATOID FACTOR; RITUXIMAB; SIMEPREVIR; SOFOSBUVIR;

ABDOMINAL PAIN; ACROCYANOSIS; ARTHRALGIA; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL (TOPIC); CRYOGLOBULINEMIA; CRYOGLOBULINEMIC VASCULITIS; EPILEPSY; FATIGUE; FINGER ULCER; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; IMMUNOBLOTTING; IMMUNOCHEMISTRY; LABORATORY DIAGNOSIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PARESTHESIA; POLYNEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PURPURA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAYNAUD PHENOMENON; REVIEW; SKIN ULCER; SMALL VESSEL VASCULITIS; COMPLICATION; HEPATITIS C; MORTALITY; SURVIVAL RATE; VASCULITIS;

CRYOGLOBULINEMIA; HEPATITIS C; HUMANS; PROGNOSIS; SURVIVAL RATE; VASCULITIS;

EID: 84940459848     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2015.02.017     Document Type: Review

References (30)

1. B. Terrier, and P. Cacoub Cryoglobulinemia vasculitis: an update Curr Opin Rheumatol 25 1 2013 10 18
2. P. Cacoub, T. Poynard, P. Ghillani, and et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C Arthritis Rheum 42 10 1999 2204 2212
3. C. Ferri, M.T. Mascia, D. Saadoun, and P. Cacoub Cryoglobulinemia and systemic manifestations of hepatitis C J.W. Bijlsma, G.R. Burmester, J.A.P. da Silva, K.L. Faarvang, E. Hachulia, X. Mariette, EULAR Compendium on Rheumatic Diseases 2009 BMJ Publishing London 616 634
4. J.C. Brouet, J.P. Clauvel, F. Danon, M. Klein, and M. Seligmann Biologic and clinical significance of cryoglobulins. A report of 86 cases Am J Med 57 5 1974 775 788
5. L. Musset, M.C. Diemert, F. Taibi, and et al. Characterization of cryoglobulins by immunoblotting Clin Chem 38 6 1992 798 802
6. O. Trejo, M. Ramos-Casals, M. García-Carrasco, and et al. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center Medicine (Baltimore) 80 4 2001 252 262
7. B. Terrier, A. Karras, J.E. Kahn, and et al. The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases Medicine (Baltimore) 92 2 2013 61 68
8. A. Tarantino, M. Campise, G. Banfi, and et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis Kidney Int 47 1995 618 623
9. C. Ferri, M. Sebastiani, D. Giuggioli, and et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients Semin Arthritis Rheum 33 2004 355 374
10. A. Della Rossa, A. Tavoni, A. D'Ascanio, and et al. Mortality rate and outcome factors in mixed cryoglobulinaemia: the impact of hepatitis C virus Scand J Rheumatol 39 2010 167 170
11. B. Terrier, O. Semoun, D. Saadoun, D. Sène, M. Resche-Rigon, and P. Cacoub Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis Arthritis Rheum 63 6 2011 1748 1757
12. L. Guillevin, C. Pagnoux, R. Seror, A. Mahr, L. Mouthon, and P. Le Toumelin The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort Medicine (Baltimore) 90 2011 19 27
13. B. Terrier, E. Krastinova, I. Marie, and et al. Management of non infectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey Blood 119 25 2012 5996 6004
14. B. Terrier, F. Carrat, E. Krastinova, and et al. Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey Ann Rheum Dis 72 3 2013 374 380
15. D. Saadoun, J. Sellam, P. Ghillani-Dalbin, R. Crecel, J.C. Piette, and P. Cacoub Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia Arch Intern Med 166 19 2006 2101 2108
16. B. Terrier, D. Launay, G. Kaplanski, and et al. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry Arthritis Care Res (Hoboken) 62 12 2010 1787 1795
17. P. Cacoub, B. Terrier, and D. Saadoun Hepatitis C virus-induced vasculitis: therapeutic options Ann Rheum Dis 73 1 2014 24 30
18. D. Saadoun, M. Resche-Rigon, V. Thibault, J.C. Piette, and P. Cacoub Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term follow up study Arthritis Rheum 54 11 2006 3696 3706
19. B. Terrier, D. Saadoun, D. Sène, and et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients Arthritis Rheum 60 8 2009 2531 2540
20. D.-A. Landau, D. Saadoun, P. Halfon, and et al. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response Arthritis Rheum 58 2 2008 604 611
21. D. Saadoun, M. Resche Rigon, S. Pol, and et al. Peg-IFNαRibavirin/Protease inhibitor combination in severe hepatitis C virus associated mixed cryoglobulinemia vasculitis J Hepatol 62 1 2015 24 30
22. L. Gragnani, A. Fabbrizzi, E. Triboli, and et al. Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study Dig Liver Dis 46 9 2014 833 837
23. European Association for Study of Liver EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 60 2 2014 392 420
24. P. Cacoub, A. Delluc, D. Saadoun, D.A. Landau, and D. Sene Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 67 3 2008 283 287
25. S. De Vita, L. Quartuccio, M. Isola, and et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis Arthritis Rheum 64 3 2012 843 853
26. M.C. Sneller, Z. Hu, and C.A. Langford A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis Arthritis Rheum 64 3 2012 835 842
27. F. Dammacco, F.A. Tucci, G. Lauletta, and et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study Blood 116 3 2010 343 353
28. D. Saadoun, M. Resche Rigon, D. Sene, and et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia Blood 116 3 2010 326 334
29. D. Saadoun, M. Pineton de Chambrun, O. Hermine, and et al. Using rituximab plus fludarabine and cyclophosphamide as a treatment for refractory mixed cryoglobulinemia associated with lymphoma Arthritis Care Res 65 4 2013 643 647
30. G. Monti, P. Pioltelli, F. Saccardo, and et al. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias Arch Intern Med 165 1 2005 101 105